Amit Khurana of Dolat Capital Market is of the view that there is opportunity in Sun Pharma and prefers midcap IT space.
first published: Aug 19, 2015 12:22 pm
A collection of the most-viewed Moneycontrol videos.

Live: Sensex, Nifty rangebound on monthly expiry day | Closing Bell

Live: Will Nifty's downtrend continue to third session on expiry day? | Opening Bell

Nifty Slips Below 26,100 Amid Sluggish Trade, Midcaps Struggle; IT Lends Support | Closing Bell Live

Live: Can Nifty reach its all-time high levels this week? | Opening Bell
You are already a Moneycontrol Pro user.

